You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 12, 2024

NEURONTIN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Neurontin, and when can generic versions of Neurontin launch?

Neurontin is a drug marketed by Viatris and is included in three NDAs.

The generic ingredient in NEURONTIN is gabapentin. There are twenty-nine drug master file entries for this compound. Seventy-six suppliers are listed for this compound. Additional details are available on the gabapentin profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Neurontin

A generic version of NEURONTIN was approved as gabapentin by ACTAVIS ELIZABETH on September 12th, 2003.

  Sign Up

Drug patent expirations by year for NEURONTIN
Drug Prices for NEURONTIN

See drug prices for NEURONTIN

Drug Sales Revenue Trends for NEURONTIN

See drug sales revenues for NEURONTIN

Recent Clinical Trials for NEURONTIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Dianne LouPhase 1/Phase 2
Viatris Specialty LLCPhase 4
CAMC Health SystemPhase 4

See all NEURONTIN clinical trials

Pharmacology for NEURONTIN

US Patents and Regulatory Information for NEURONTIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Viatris NEURONTIN gabapentin CAPSULE;ORAL 020235-001 Dec 30, 1993 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Viatris NEURONTIN gabapentin SOLUTION;ORAL 021129-001 Mar 2, 2000 AA RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Viatris NEURONTIN gabapentin CAPSULE;ORAL 020235-002 Dec 30, 1993 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Viatris NEURONTIN gabapentin CAPSULE;ORAL 020235-003 Dec 30, 1993 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Viatris NEURONTIN gabapentin TABLET;ORAL 020882-002 Oct 9, 1998 AB1 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Viatris NEURONTIN gabapentin TABLET;ORAL 020882-001 Oct 9, 1998 AB1 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for NEURONTIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Viatris NEURONTIN gabapentin TABLET;ORAL 020882-001 Oct 9, 1998 ⤷  Sign Up ⤷  Sign Up
Viatris NEURONTIN gabapentin SOLUTION;ORAL 021129-001 Mar 2, 2000 ⤷  Sign Up ⤷  Sign Up
Viatris NEURONTIN gabapentin CAPSULE;ORAL 020235-003 Dec 30, 1993 ⤷  Sign Up ⤷  Sign Up
Viatris NEURONTIN gabapentin TABLET;ORAL 020882-002 Oct 9, 1998 ⤷  Sign Up ⤷  Sign Up
Viatris NEURONTIN gabapentin TABLET;ORAL 020882-001 Oct 9, 1998 ⤷  Sign Up ⤷  Sign Up
Viatris NEURONTIN gabapentin CAPSULE;ORAL 020235-001 Dec 30, 1993 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for NEURONTIN

See the table below for patents covering NEURONTIN around the world.

Country Patent Number Title Estimated Expiration
Dominican Republic P2002000403 COMPOSICION FARMACEUTICA LIQUIDA ⤷  Sign Up
Canada 2446574 COMPOSITION PHARMACEUTIQUE LIQUIDE (LIQUID PHARMACEUTICAL COMPOSITION) ⤷  Sign Up
Switzerland 612664 ⤷  Sign Up
Japan 3261123 ⤷  Sign Up
Malaysia 128615 LIQUID PHARMACEUTICAL COMPOSITION ⤷  Sign Up
Iceland 2428 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.